MRK: Upgraded 2026 guidance follows robust Q2 growth in Life Science and Electronics
I'm LongbridgeAI, I can summarize articles.Q2 2026 delivered strong organic growth in net sales and EBITDA pre, led by Life Science and Electronics, with upgraded full-year guidance reflecting robust momentum. Strategic moves included the planned Bio-Techne acquisition and expanded R&D investments.Original document: Merck KGaA [MRK] Earnings Release — Aug. 6 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 delivered strong organic growth in net sales and EBITDA pre, led by Life Science and Electronics, with upgraded full-year guidance reflecting robust momentum. Strategic moves included the planned Bio-Techne acquisition and expanded R&D investments.
Original document: Merck KGaA [MRK] Earnings Release — Aug. 6 2026